Combined PD-1/PD-L1 inhibitor monotherapy based on platinum-based chemotherapy demonstrates a relatively higher response rate, a prolonged survival time, and a favorable adverse event profile in the treatment of advanced NSCLC according to several studies (3, 4). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.